Papillomavirus Prophylactic Vaccines: Established Successes, New Approaches

被引：41

作者：

Campo, M. Saveria ^{[1
]}

Roden, Richard B. S. ^{[2
]}

机构：

[1] Univ Glasgow, Div Pathol Sci, Inst Comparat Med, Glasgow G61 1QH, Lanark, Scotland

[2] Johns Hopkins Univ, Dept Pathol, Baltimore, MD 21231 USA

来源：

JOURNAL OF VIROLOGY | 2010年 / 84卷 / 03期

基金：

美国国家卫生研究院;

关键词：

VIRUS-LIKE PARTICLES; CROSS-NEUTRALIZING EPITOPE; L2E6E7 FUSION PROTEIN; N-TERMINUS; CAPSID PROTEIN; THERAPEUTIC VACCINATION; DIFFERENT MECHANISMS; HEPARAN-SULFATE; DOWN-REGULATION; E5; PROTEIN;

D O I：

10.1128/JVI.01927-09

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Vaccines against the human papillomaviruses (HPVs) most frequently associated with cancer of the cervix are now available. These prophylactic vaccines, based on virus-like particles (VLPs), are extremely effective, providing protection from infection in almost 100% of cases. However, the vaccines present some limitations: they are effective primarily against the HPV type present in the vaccine, are expensive to produce, and need a cold chain. Vaccines based on the minor capsid protein L2 have been very successful in animal models and have been shown to provide a good level of protection against different papillomavirus types. The potential of L2-based vaccines to protect against many types of HPVs is discussed.

引用

页码：1214 / 1220

页数：7